Compare TRNO & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRNO | GRFS |
|---|---|---|
| Founded | 2009 | 1940 |
| Country | United States | Spain |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.2B |
| IPO Year | 2010 | 2006 |
| Metric | TRNO | GRFS |
|---|---|---|
| Price | $62.48 | $9.23 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 12 | 2 |
| Target Price | ★ $65.58 | $10.15 |
| AVG Volume (30 Days) | ★ 685.8K | 459.5K |
| Earning Date | 02-05-2026 | 07-28-2022 |
| Dividend Yield | ★ 3.33% | 1.54% |
| EPS Growth | ★ 75.67 | N/A |
| EPS | ★ 3.15 | 0.64 |
| Revenue | $442,611,000.00 | ★ $8,821,017,248.00 |
| Revenue This Year | $23.60 | $5.36 |
| Revenue Next Year | $7.96 | $5.15 |
| P/E Ratio | $19.87 | ★ $17.85 |
| Revenue Growth | ★ 21.13 | 7.31 |
| 52 Week Low | $48.18 | $6.19 |
| 52 Week High | $69.20 | $11.14 |
| Indicator | TRNO | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 60.99 | 53.93 |
| Support Level | $58.77 | $8.63 |
| Resistance Level | $63.17 | $9.40 |
| Average True Range (ATR) | 1.15 | 0.23 |
| MACD | 0.34 | -0.02 |
| Stochastic Oscillator | 82.57 | 65.43 |
Terreno Realty Corp is a real estate investment trust engaged in acquiring, owning, and operating industrial real estate in six coastal U.S. markets: Los Angeles, Northern New Jersey/New York City, San Francisco Bay Area, Seattle, Miami, and Washington, D.C. The company invests in several types of industrial real estate, including warehouse/distribution, flex (including light industrial and research and development), transshipment, and improved land.
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.